Form 4: Lexeo Therapeutics Executive Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics, acquired stock options and restricted stock units (RSUs) as part of an equity grant.
Summary
- On June 12, 2024, Jose Manuel Otero, the Chief Technical Officer of Lexeo Therapeutics, acquired 31,250 restricted stock units (RSUs) and stock options for 187,500 shares.
- The RSUs vest 25% on August 15, 2025, and then quarterly.
- The stock options vest 25% on May 20, 2025, and then monthly.
- The exercise price of the stock options is $18.19.
- Following these transactions, Otero directly owns 31,250 shares of common stock and holds options for 187,500 shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, indicating confidence in the company's future performance. The vesting schedules suggest a long-term commitment from the executive.
Positives
- The equity grants align the executive's interests with those of the shareholders.
- The vesting schedules encourage long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the equity grants.
Industry Context
Equity compensation is a common practice in the biotechnology industry to attract and retain talent, aligning executive incentives with company performance and shareholder value.
Comparison to Industry Standards
- Equity grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
- Vesting schedules, such as the quarterly and monthly installments described, are typical for these types of grants.
- Comparable companies like BioMarin, Sarepta Therapeutics, and Vertex Pharmaceuticals also utilize stock options and RSUs in their executive compensation plans.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 06/12/2024 | Date of transaction: Acquisition of RSUs and stock options |
| 08/15/2025 | First vesting date for 25% of the RSUs |
| 05/20/2025 | First vesting date for 25% of the stock options |
| 06/11/2034 | Expiration date of the stock options |
| 06/14/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.